Diana Brainard
CIK: 0001818070
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- Sep 23, 2026NKTR
NEKTAR THERAPEUTICS
Award(A)Direct2K shares- - Sep 30, 2025NKTR
NEKTAR THERAPEUTICS
Award(A)DirectStock Option
8K shares- - Nov 19, 2024ALVR
Allovir, Inc.
Sale(S)Direct8.7K shares at avg. $0.55$5K - Nov 5, 2024ALVR
Allovir, Inc.
Sale(S)Direct10.6K shares at avg. $0.86$9K - Oct 21, 2024ALVR
Allovir, Inc.
Sale(S)Direct9.8K shares at avg. $0.78$8K - Oct 3, 2024ALVR
Allovir, Inc.
Sale(S)Direct1.5K shares at avg. $0.81$1K - Sep 18, 2024NKTR
NEKTAR THERAPEUTICS
Award(A)DirectStock Option
120K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 23, 2026 | NKTR NEKTAR THERAPEUTICS | Award(A) | 2,000 | - | $0 | Direct |
| Sep 30, 2025 | NKTR NEKTAR THERAPEUTICS | Award(A) Stock Option | 8,000 | - | - | Direct |
| Nov 19, 2024 | ALVR Allovir, Inc. | Sale(S) | 8,706 | $0.55 | $4,775 | Direct |
| Nov 5, 2024 | ALVR Allovir, Inc. | Sale(S) | 10,609 | $0.86 | $9,176 | Direct |
| Oct 21, 2024 | ALVR Allovir, Inc. | Sale(S) | 9,752 | $0.78 | $7,597 | Direct |
| Oct 3, 2024 | ALVR Allovir, Inc. | Sale(S) | 1,493 | $0.81 | $1,216 | Direct |
| Sep 18, 2024 | NKTR NEKTAR THERAPEUTICS | Award(A) Stock Option | 120,000 | - | - | Direct |
1-7 of 7 transactions
About Brainard Diana
Brainard Diana (SEC CIK 0001818070) files insider reports with the SEC as Director of NEKTAR THERAPEUTICS (NKTR) and Chief Executive Officer of Allovir, Inc. (ALVR).
Signal8 holds 7 ownership filings by Brainard Diana (6 Form 4, 1 Form 5), filed between Oct 4, 2024 and Sep 25, 2026. Those filings report 7 transactions, from Sep 18, 2024 to Sep 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Brainard Diana's filings is in SAN FRANCISCO, CA.
Recent filings by Brainard Diana
- Sep 23, 2026: Grant or award of NKTR shares (Form 4, code A).
- Sep 30, 2025: Grant or award of NKTR derivative securities (Form 4, code A).
- Nov 19, 2024: Open-market sale of ALVR shares (Form 4, code S).
- Nov 5, 2024: Open-market sale of ALVR shares (Form 4, code S).
- Oct 21, 2024: Open-market sale of ALVR shares (Form 4, code S).
Other insiders filing for NEKTAR THERAPEUTICS (NKTR)
- WHITFIELD ROY A, Director
- GREER R SCOTT, Director
- CHESS ROBERT, Director
- Ajer Jeffrey Robert, Director
- Zalevsky Jonathan, Chief R&D Officer
- ROBIN HOWARD W, President & CEO